Company Overview and News


Add PAR
to your dashboard

Headline News

Paradigm reveals outcomes from patient case studies on Osteoarthritis

2017-10-11 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd (ASX:PAR) has outlined the results of 24 patient case studies with Osteoarthritis (OA) and Bone Marrow Edema Lesions (BMELs) that were treated with Pentosan Polysulfate Sodium (PPS) under the Therapeutic Goods Administration’s (TGA) Special Access Scheme.

Paradigm Biopharmaceuticals receives ethics approval for trial on knee osteoarthritis

2017-09-20 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd (ASX:PAR) has received ethics approval for its Phase 2b clinical trial to investigate Pentosan Polysulfate Sodium (PPS) in subjects with knee osteoarthritis (OA) and bone marrow edema lesions (BMELs).

Paradigm Biopharmaceuticals shares continue uptrend on leverage to Pentosan Polysulfate Sodium

2017-09-16 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd (ASX:PAR) has added another 2% to $0.40 in early trade, after jumping 40% yesterday, following a peer-reviewed publication.

Paradigm Biopharmaceuticals shares jump 75% in morning trade

2017-09-16 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd (ASX:PAR) has caught investor attention this morning with its shares jumping 75% following the publication of a peer-reviewed journal of the potential of Pentosan Polysulfate Sodium (PPS).

Paradigm's Paul Rennie discusses momentum of the Ross River Virus Clinical Trial

2017-09-14 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd (ASX:PAR) continues to advance its Phase 2 Ross River Virus Clinical Trial, with 25% of the 24-participant total having now been dosed across the initial two trial sites in Geelong and Brisbane.

Paradigm Biopharmaceuticals doses first Ross River participant

2017-08-09 proactiveinvestors.com.au
Paradigm Biopharmaceuticals (ASX:PAR) has successfully dosed its first participant in its Phase 2 Alphavirus clinical trial of the drug pentosan polysulfate sodium (PPS) for the treatment of Ross River virus.

Paradigm Biopharmaceuticals Ltd to commence Ross River trial

2017-07-10 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd (ASX:PAR) is now ready to commence its Phase 2 Alphavirus clinical trial of the drug pentosan polysulfate sodium (PPS) for the treatment of Ross River virus.

Paradigm Biopharmaceuticals CEO lifts stake over 22%

2017-06-28 proactiveinvestors.com.au
Paradigm Biopharmaceuticals (ASX:PAR) chief executive officer, Paul Rennie, is a major shareholder in the company and on-market purchases have lifted him to a 22.06% stake.

Paradigm Biopharmaceuticals CEO buys shares on-market

2017-06-26 proactiveinvestors.com.au
Paradigm Biopharmaceuticals (ASX:PAR) has received a vote of confidence from its CEO and director, Paul Rennie, who has purchased $100,618.95 worth of shares on-market.

Paradigm Biopharmaceuticals enters US$18 billion global heart failure market

2017-06-20 proactiveinvestors.com.au
Paradigm Biopharmaceuticals (ASX:PAR) has expanded its drug development pipeline by in-licensing Pentosan Polysulfate Sodium (PPS) for the treatment of heart failure from the University of Oslo, Norway.

Paradigm Biopharmaceuticals receives hay fever update

2017-06-16 proactiveinvestors.com.au
Paradigm Biopharmaceuticals (ASX:PAR) has been verbally informed that its Phase 2a allergic rhinitis (hay fever) clinical trial did not meet its primary endpoints.

Paradigm Biopharmaceuticals in a trading halt as news pending

2017-06-15 proactiveinvestors.com.au
Paradigm Biopharmaceuticals (ASX:PAR) has been granted a trading halt by the ASX, with its shares placed in pre-open.

Paradigm Biopharmaceuticals gets approval for Ross River trial

2017-05-22 proactiveinvestors.com.au
Paradigm Biopharmaceuticals (ASX:PAR) has received ethics approval  for its Phase 2 clinical trial of the drug pentosan polysulfate sodium (PPS) for the treatment of Ross River virus.

Paradigm Biopharmaceuticals: Access latest PPT from Proactive's CEO Sessions

2017-05-19 proactiveinvestors.com.au
Paradigm Biopharmaceuticals (ASX:PAR) chief executive officer, Paul Rennie, joined Proactive's CEO Sessions in Melbourne on Tuesday 16th May and Sydney on Wednesday 17th May.

Paradigm Biopharmaceuticals has hay fever study published

2017-05-16 proactiveinvestors.com.au
Paradigm Biopharmaceuticals (ASX:PAR) has had the preclinical study validating the efficacy of its drug, pentosan polysulfate sodium (PPS), published in a peer-reviewed scientific journal.

Paradigm Biopharmaceuticals receives valuable grant

2017-05-11 proactiveinvestors.com.au
Paradigm Biopharmaceuticals (ASX:PAR) has received a $300,000 government grant for the development of a treatment that could be the first to combat the Ross River virus.

Paradigm Biopharmaceuticals brings Phase 2 milestone news flow to Spotlight CEO Sessions

2017-05-08 proactiveinvestors.com.au
Paradigm Biopharmaceuticals (ASX:PAR) has key milestone news flow pending. The company is fully-funded through to the completion of the Phase 2 open label clinical trial for bone bruising, Phase 2 hay fever and Phase 2 alpha viruses trials. The results have the potential to generate interest from Big Pharma. Find out more from Paul Rennie at Proactive's CEO Sessions.

The Hydroponics Company brings immediate cash flow to Spotlight CEO Sessions

2017-05-07 proactiveinvestors.com.au
The Hydroponics Company (ASX:THC) made a barnstorming debut on the ASX last week, with the shares trading at close to double the IPO entry point of $0.20 per share.

White Rock Minerals to show case silver-zinc at Spotlight CEO Sessions

2017-05-05 proactiveinvestors.com.au
White Rock Minerals (ASX:WRM) recently delivered a value adding asset into its portfolio, with a resource from its wholly-owned Red Mountain project in Alaska.

Paradigm Biopharmaceuticals treats final patient in hay fever trial

2017-03-23 proactiveinvestors.com.au
Paradigm Biopharmaceuticals (ASX:PAR) has achieved a major clinical milestone in its Phase 2 hay fever trial, with the successful treatment of the last clinical trial participant.

Paradigm Biopharmaceuticals gets cash boost from rebate

2017-03-22 proactiveinvestors.com.au
Paradigm Biopharmaceuticals (ASX:PAR) has received a research and development tax incentive rebate of $1.34 million for expenditure undertaken during the 2016 financial year.

Paradigm Biopharmaceuticals to test Ross River treatment

2017-03-07 proactiveinvestors.com.au
Paradigm Biopharmaceuticals (ASX:PAR) is currently preparing to test a treatment that could be the first to combat the Ross River virus.

Paradigm Biopharmaceuticals shines under broker spotlight

2017-03-02 proactiveinvestors.com.au
Paradigm Biopharmaceuticals (ASX:PAR) focused on repurposing the historic drug PPS (Pentosan Polysulfate Sodium) as a potential new treatment for Bone Marrow Edema (BME) lesions following traumatic injury.

Paradigm Biopharmaceuticals Ltd clears initial safety review of nasal spray

2016-08-19 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd (ASX:PAR) has completed Phase 1 clinical trial of pentosan polysulfate sodium (PPS) for the treatment of allergic rhinitis (hay fever), without any significant safety concerns in treated participants. The study was conducted on 18 healthy volunteers and is the first ever to evaluate the nasal route of administration for Paradigm’s PPS nasal spray, Rhinosul. The trial follows a 28-day intra-nasal toxicology study in rats which concluded no adverse effects at any tested dose, with results supporting a safety margin of up to 20 times the estimated human dose.

Appendix 3B

2016-05-09 asx.com.au